Edition:
United States

Imv Inc (IMV.TO)

IMV.TO on Toronto Stock Exchange

6.31CAD
3:59pm EDT
Change (% chg)

$0.11 (+1.77%)
Prev Close
$6.20
Open
$6.16
Day's High
$6.40
Day's Low
$6.16
Volume
23,200
Avg. Vol
43,427
52-wk High
$9.49
52-wk Low
$3.33

Latest Key Developments (Source: Significant Developments)

IMV Inc Reports Q1 Loss Per Share $0.7
Monday, 14 May 2018 04:35pm EDT 

May 14 (Reuters) - Imv Inc ::IMV INC. (FORMERLY IMMUNOVACCINE INC.) ANNOUNCES Q1 2018 FINANCIAL RESULTS.IMV INC - QTRLY LOSS PER SHARE $0.7.  Full Article

Immunovaccine And Incyte Expand Clinical Collaboration
Tuesday, 24 Apr 2018 07:05am EDT 

April 24 (Reuters) - Immunovaccine Inc ::IMMUNOVACCINE AND INCYTE EXPAND CLINICAL COLLABORATION EVALUATING COMBINATION IMMUNOTHERAPIES IN ADVANCED RECURRENT OVARIAN CANCER.IMMUNOVACCINE - COS PLAN TO ADD PHASE 2 COMPONENT TO ONGOING PHASE 1B STUDY OF DXP-SURVIVAC WITH INCYTE'S EPACADOSTAT AND LOW DOSE CYCLOPHOSPHAMIDE.IMMUNOVACCINE - PHASE 2 ARM OF STUDY TO BE CONDUCTED UNDER AMENDMENT TO EXISTING COLLABORATION, IN WHICH IMMUNOVACCINE & INCYTE ARE CO-FUNDING TRIAL.IMMUNOVACCINE INC - EXPECTS TO PROVIDE A CLINICAL UPDATE ON PHASE 1B PROGRAM IN FIRST HALF OF 2018.  Full Article

Immunovaccine announces positive clinical data from its collaborative combination immunotherapy trial in advanced ovarian cancer
Tuesday, 5 Dec 2017 07:05am EST 

Dec 5 (Reuters) - Immunovaccine Inc ::IMMUNOVACCINE ANNOUNCES POSITIVE CLINICAL DATA FROM ITS COLLABORATIVE COMBINATION IMMUNOTHERAPY TRIAL IN ADVANCED OVARIAN CANCER.IMMUNOVACCINE INC - ‍DATA FROM FIRST DOSING COHORT FROM COLLABORATIVE COMBINATION IMMUNOTHERAPY TRIAL​ SHOW A 70% DISEASE CONTROL RATE DATA.IMMUNOVACCINE - EXPECTS TO PROVIDE CLINICAL UPDATE ON SECOND DOSING COHORT OF DPX-SURVIVAC IN FIRST HALF OF 2018.IMMUNOVACCINE - ‍DATA FROM FIRST DOSING COHORT FROM COLLABORATIVE COMBINATION IMMUNOTHERAPY TRIAL FOR DPX-SURVIVAC​DEMONSTRATE TOLERABLE SAFETY PROFILE.  Full Article

Immunovaccine reports qtrly loss per share of ‍$0.02​
Thursday, 9 Nov 2017 05:05pm EST 

Nov 9 (Reuters) - Immunovaccine Inc :Immunovaccine announces third quarter 2017 financial results.Immunovaccine Inc qtrly loss per share ‍$0.02​.  Full Article

Immunovaccine announces regulatory clearance for Phase 2 clinical trial evaluating DPX-Survivac
Wednesday, 8 Nov 2017 07:05am EST 

Nov 8 (Reuters) - Immunovaccine Inc ::Immunovaccine announces regulatory clearance for Phase 2 clinical trial evaluating DPX-Survivac in combination with Merck's checkpoint inhibitor Pembrolizumab in DLBCL.  Full Article

Immunovaccine Inc CFO Kimberly Stephens steps down
Monday, 3 Oct 2016 07:05am EDT 

Immunovaccine Inc : Has begun process of hiring a new CFO . Immunovaccine announces transition of chief financial officer role . Chief financial officer (CFO) Kimberly Stephens is departing company .Stephens will continue to work with Immunovaccine through December 2016.  Full Article

Immunovaccine names Frederic Ors permanent CEO
Tuesday, 9 Aug 2016 05:05pm EDT 

Immunovaccine Inc : Immunovaccine provides corporate update and announces second quarter 2016 financial results . Says securing $8 million in a bought deal private placement financing . Immunovaccine Inc says appointing Medicago CEO and president Andy Sheldon as board chairman, and CTI LSF's Shermaine Tilley as a board director . Says "ceasing our Pharmathene collaboration related to anthrax" . Says naming Frederic Ors permanent chief executive officer . Says initiating a search for a chief medical officer .Qtrly net loss and comprehensive loss of $1.4 million.  Full Article

BRIEF-Immunovaccine Announces $12.5 Million Bought Deal Offering

* IMMUNOVACCINE INC - ENTERED INTO BOUGHT DEAL FINANCING AGREEMENT TO SELL 6.3 MILLION COMMON SHARES AT A PRICE OF $2.00 PER COMMON SHARE Source text for Eikon: Further company coverage: